Incyte Corporation
IndexS&P 500 P/E18.06 EPS (ttm)4.20 Insider Own0.40% Shs Outstand221.33M Perf Week2.90%
Market Cap16.08B Forward P/E16.68 EPS next Y4.55 Insider Trans- Shs Float218.09M Perf Month-1.68%
Income933.00M PEG1.21 EPS next Q0.74 Inst Own95.50% Short Float2.59% Perf Quarter-4.79%
Sales3.11B P/S5.16 EPS this Y415.00% Inst Trans1.63% Short Ratio3.91 Perf Half Y3.53%
Book/sh17.45 P/B4.35 EPS next Y41.69% ROA20.60% Target Price91.86 Perf Year-10.40%
Cash/sh12.01 P/C6.32 EPS next 5Y14.90% ROE27.20% 52W Range61.91 - 85.97 Perf YTD3.39%
Dividend- P/FCF26.39 EPS past 5Y51.40% ROI25.30% 52W High-11.73% Beta0.67
Dividend %- Quick Ratio3.70 Sales past 5Y22.00% Gross Margin95.40% 52W Low22.58% ATR2.19
Employees2094 Current Ratio3.70 Sales Q/Q21.30% Oper. Margin19.40% RSI (14)54.92 Volatility2.49% 2.87%
OptionableYes Debt/Eq0.01 EPS Q/Q-29.40% Profit Margin30.00% Rel Volume0.49 Prev Close75.63
ShortableYes LT Debt/Eq0.01 EarningsMay 03 BMO Payout0.00% Avg Volume1.44M Price75.89
Recom2.10 SMA203.88% SMA501.39% SMA2005.51% Volume706,596 Change0.34%
Feb-09-22Downgrade SVB Leerink Mkt Perform → Underperform $60 → $56
Jan-18-22Upgrade RBC Capital Mkts Sector Perform → Outperform $78 → $90
Nov-19-21Initiated BMO Capital Markets Market Perform $75
Jul-20-21Upgrade The Benchmark Company Hold → Buy $89
Feb-10-21Downgrade SVB Leerink Mkt Perform → Underperform $70
Jan-07-21Initiated Truist Buy $120
Jan-04-21Upgrade Guggenheim Neutral → Buy
Jun-16-20Initiated The Benchmark Company Hold
May-06-20Downgrade JP Morgan Overweight → Neutral $89 → $99
Apr-29-20Downgrade Morgan Stanley Overweight → Equal-Weight $94
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Jun-29-22 06:17AM  
Jun-26-22 07:45AM  
Jun-17-22 05:00AM  
Jun-14-22 11:00AM  
Jun-13-22 09:50PM  
Jun-07-22 03:25PM  
Jun-02-22 01:24PM  
May-26-22 06:00AM  
May-24-22 08:00AM  
May-23-22 11:33AM  
May-20-22 02:53PM  
May-18-22 11:23AM  
May-13-22 01:49PM  
May-12-22 08:02AM  
May-11-22 07:04AM  
May-05-22 01:20AM  
May-04-22 04:15PM  
May-03-22 02:05PM  
May-02-22 03:55PM  
May-01-22 06:15AM  
Apr-28-22 04:05PM  
Apr-27-22 12:17PM  
Apr-26-22 03:01PM  
Apr-25-22 01:16PM  
Apr-22-22 12:00PM  
Apr-20-22 11:03AM  
Apr-12-22 08:00AM  
Apr-05-22 02:55PM  
Mar-28-22 10:12AM  
Mar-26-22 11:20AM  
Mar-25-22 08:30AM  
Mar-24-22 11:00AM  
Mar-23-22 07:05AM  
Mar-18-22 09:56AM  
Mar-16-22 12:32PM  
Mar-15-22 11:37AM  
Mar-14-22 08:00AM  
Mar-10-22 11:30AM  
Mar-04-22 10:50AM  
Mar-03-22 03:37PM  
Mar-01-22 07:55AM  
Feb-18-22 08:30PM  
Feb-15-22 08:00AM  
Feb-09-22 07:38AM  
Feb-08-22 12:24PM  
Feb-07-22 09:53AM  
Feb-06-22 03:37PM  
Feb-03-22 05:38PM  
Jan-31-22 11:19AM  
Jan-28-22 11:04AM  
Jan-27-22 10:27AM  
Jan-26-22 07:07AM  
Jan-25-22 04:30PM  
Jan-21-22 01:38PM  
Jan-20-22 07:03AM  
Jan-18-22 08:00AM  
Jan-06-22 05:38PM  
Dec-16-21 08:36AM  
Dec-15-21 09:06AM  
Dec-14-21 04:30PM  
Dec-13-21 08:45PM  
Dec-11-21 12:00PM  
Dec-08-21 07:38PM  
Dec-06-21 10:04AM  
Dec-02-21 11:31AM  
Nov-09-21 08:30AM  
Nov-04-21 10:07AM  
Nov-02-21 12:00PM  
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flannelly Barry PEVP & General Manager USApr 08Option Exercise70.4841,8642,950,62888,640Apr 12 04:10 PM
Flannelly Barry PEVP & General Manager USApr 08Sale83.4943,9933,672,88765,163Apr 12 04:10 PM
BAKER BROS. ADVISORS LPDirectorMar 10Buy73.13218,56315,982,72033,419,055Mar 10 06:02 PM
BAKER BROS. ADVISORS LPDirectorMar 09Buy71.7270,5175,057,55033,217,136Mar 10 06:02 PM
BAKER BROS. ADVISORS LPDirectorMar 08Option Exercise22.0540,000882,00033,059,604Mar 10 06:02 PM
BAKER BROS. ADVISORS LPDirectorMar 08Buy70.67100,0007,067,50033,151,989Mar 10 06:02 PM
BAKER BROS. ADVISORS LPDirectorFeb 22Buy68.0799,8006,793,53633,039,604Feb 22 05:45 PM
BAKER BROS. ADVISORS LPDirectorFeb 18Buy68.38133,0329,096,55032,947,370Feb 22 05:45 PM
BAKER BROS. ADVISORS LPDirectorFeb 17Buy67.74292,97219,844,80532,824,461Feb 22 05:45 PM
Dickinson Jonathan ElliottEVP, General Manager, EuropeJan 31Sale74.197,375547,15130,214Feb 02 04:25 PM
SWAIN PAULA JEVP, Human ResourcesJan 07Option Exercise73.2110,870795,79383,241Jan 11 04:18 PM
SWAIN PAULA JEVP, Human ResourcesJan 07Sale73.3110,870796,88072,371Jan 11 04:18 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise73.219,319682,24481,690Jan 05 04:25 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale73.469,319684,57472,371Jan 05 04:25 PM
Trower PaulPrincipal Accounting OfficerJan 03Option Exercise73.218,214601,34739,086Jan 05 04:40 PM
Trower PaulPrincipal Accounting OfficerJan 03Sale73.318,214602,16832,268Jan 05 04:40 PM
DIXON WENDY LDirectorDec 23Option Exercise73.2520,0001,465,00037,259Dec 27 04:11 PM
DIXON WENDY LDirectorDec 23Sale22.0520,000441,00017,259Dec 27 04:11 PM
BAKER BROS. ADVISORS LPDirectorDec 17Buy72.801,075,87278,322,14830,932,696Dec 17 06:30 PM
BAKER BROS. ADVISORS LPDirectorDec 16Buy71.96169,31512,184,41129,856,824Dec 17 06:30 PM
BAKER BROS. ADVISORS LPDirectorDec 15Buy71.51350,33225,052,34029,687,509Dec 17 06:30 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 01Sale68.6738926,71331,263Oct 04 04:41 PM
Pasquale Maria EEVP & General CounselSep 24Option Exercise65.3638224,96836,187Sep 28 08:18 AM
SWAIN PAULA JEVP, Human ResourcesSep 20Option Exercise73.211,35699,27360,959Sep 21 04:09 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 01Sale76.7138829,76331,652Sep 03 07:40 AM
Dhanak DashyantEVP & Chief Scientific OfficerAug 02Sale77.4938930,14432,040Aug 04 04:16 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 29Sale78.294,911384,48227,005Aug 02 04:14 PM